ニューヨークにおける過体重の臨床試験
ニューヨーク内の拠点で、過体重に関する45件の研究が参加者を募集しています。
ニューヨーク内の都市
- New York City19件の研究
- Rochester13件の研究
- Buffalo7件の研究
- Cheektowaga4件の研究
- Manhattan4件の研究
- Syracuse4件の研究
- Queens3件の研究
- Brooklyn3件の研究
- Albany3件の研究
公式研究テキスト（英語）
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
- Weill Cornell -1300 York Avenue, New York
- Lenox Hill Hospital | Northwell Health, New York
被験者募集中
21歳〜65歳 · 全性別 · 2026/10/01更新 · NCT07090005Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Rochester Clinical Research /ID# 282484, Rochester
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Southgate Medical Group, LLP, West Seneca
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- UBMD Physicians Group - Pediatrics - Conventus, Buffalo
- SUNY Upstate Medical Univ - Syracuse, Syracuse
- Advantage Clinical Trials, The Bronx
被験者募集中第3相
8歳〜18歳 · 全性別 · 2026/09/30更新 · NCT07253285Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- Rochester Clinical Research, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07685808AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Comprehensive Weight Ctrl Prog, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Ichor Research, Syracuse
- Southgate Medical Group, LLP, West Seneca
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07668414Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- ALSA Research-Manhattan, New York
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Drug Trials America, Hartsdale
- NYC Research INC, Long Island City
- Rochester Clinical Research, LLC, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Weill Cornell Medicine - Comprehensive Weight Control Center, New York
- Rochester Clinical Research, LLC, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UBMD Pediatrics, Buffalo
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Rochester Clinical Research, LLC, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Binghamton, Binghamton
- Hudson Valley Cardiovascular Practice PC, Poughkeepsie
- Rochester Clinical Research, Rochester
- 他2件
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
- IMA Clinical Research Manhattan, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Rochester Clinical Research - Buffalo, Buffalo
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07369011A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Dent Neurologic Institute, Amherst
- Rochester Clinical Research, LLC, Rochester
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/22更新 · NCT07589608Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Ellipsis Research Group - Brooklyn - 7th Street, Brooklyn
- Rochester Clinical Research - Buffalo, Buffalo
- NYC Research INC, Long Island City
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NYC Research INC, Long Island City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07282600A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, New Windsor
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, East Northport
- AURORA-2 Clinical Site, East Syracuse
- AURORA-2 Clinical Site, New Windsor
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- NYC Research INC, Long Island City
- Richmond University Medical Center, Staten Island
- Southgate Medical Group, West Seneca
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Rochester Clinical Research, Buffalo
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Albany
- ACCOMPLISH-2 Research Site, Albany
- ACCOMPLISH-2 Research Site, Brooklyn
- 他1件
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Weil Cornell Medicine, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT07571005AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Weil Cornell Medicine, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07571109A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Dent Neurologic Institute, Amherst
- Velocity Clinical Research, Syracuse, East Syracuse
- Rochester Clinical Research, LLC, Rochester
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Equity Medical, New York
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06857942Alpelisib Challenge Test (ACT)
- Columbia University Irving Medical Center, New York
被験者募集中第1相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/09/03更新 · NCT07778524Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Velocity Clinical Research- Binghamton, Binghamton
- Rochester Clinical Research, Rochester
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Albany
- Kailera Clinical Site, Laurelton
- Kailera Clinical Site, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284901Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- Mexican Consulate's Ventanilla de Salud (VDS), New York
被験者募集中第2相健康なボランティア歓迎
21歳以上 · 全性別 · 2026/09/02更新 · NCT05770570Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Icahn School of Medicine at Mount Sinai, New York
- Rochester Clinical Research, Rochester
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/27更新 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Cortland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07784725Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
被験者募集中第1相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/08/24更新 · NCT06354088AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- NYU Langone Orthopedic Center, New York
- Hospital For Special Surgery, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Albany
- ACCOMPLISH-1 Research Site, Brooklyn
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
- State University of New York at Buffalo, South Campus, Buffalo
被験者募集中
18歳〜60歳 · 全性別 · 2026/06/11更新 · NCT07641361ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。